Literature DB >> 26600112

New Developments in Insomnia Medications of Relevance to Mental Health Disorders.

Andrew D Krystal1.   

Abstract

Many insomnia medications with high specificity have become available recently. They provide a window into the clinical effects of modulating specific brain systems and establish a new guiding principal for conceptualizing insomnia medications: "mechanism matters." A new paradigm for insomnia therapy in which specific drugs are selected to target the specific type of sleep difficulty for each patient includes administering specific treatments for patients with insomnia comorbid with particular psychiatric disorders. This article reviews insomnia medications and discusses the implications for optimizing the treatment of insomnia occurring comorbid with psychiatric conditions.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Comorbid psychiatric disorders; Doxepin; Eszopiclone; Insomnia; Personalization; Prazosin; Suvorexant

Mesh:

Substances:

Year:  2015        PMID: 26600112      PMCID: PMC5972036          DOI: 10.1016/j.psc.2015.08.001

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  49 in total

1.  Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors:  David Michelson; Ellen Snyder; Erin Paradis; Mary Chengan-Liu; Duane B Snavely; Jill Hutzelmann; James K Walsh; Andrew D Krystal; Ruth M Benca; Martin Cohn; Christopher Lines; Thomas Roth; W Joseph Herring
Journal:  Lancet Neurol       Date:  2014-03-27       Impact factor: 44.182

Review 2.  Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications.

Authors:  Andrew D Krystal; Elliott Richelson; Thomas Roth
Journal:  Sleep Med Rev       Date:  2013-01-26       Impact factor: 11.609

3.  Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.

Authors:  Andrew D Krystal; Alan Lankford; H Heith Durrence; Elizabeth Ludington; Philip Jochelson; Roberta Rogowski; Thomas Roth
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

4.  Chronic insomnia and activity of the stress system: a preliminary study.

Authors:  A N Vgontzas; C Tsigos; E O Bixler; C A Stratakis; K Zachman; A Kales; A Vela-Bueno; G P Chrousos
Journal:  J Psychosom Res       Date:  1998-07       Impact factor: 3.006

5.  The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.

Authors:  Juthamas Wirojanan; Sebastien Jacquemont; Rafael Diaz; Susan Bacalman; Thomas F Anders; Randi J Hagerman; Beth L Goodlin-Jones
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

6.  The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease.

Authors:  Meir Kryger; Thomas Roth; Sherry Wang-Weigand; Jeffrey Zhang
Journal:  Sleep Breath       Date:  2008-06-27       Impact factor: 2.816

7.  Diphenhydramine in insomniac family practice patients: a double-blind study.

Authors:  K Rickels; R J Morris; H Newman; H Rosenfeld; H Schiller; R Weinstock
Journal:  J Clin Pharmacol       Date:  1983 May-Jun       Impact factor: 3.126

Review 8.  A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice.

Authors:  Andrew D Krystal
Journal:  Sleep Med Rev       Date:  2009-01-18       Impact factor: 11.609

9.  Brief report: melatonin facilitates sleep in individuals with mental retardation and insomnia.

Authors:  H Niederhofer; W Staffen; A Mair; Klaus Pittschieler
Journal:  J Autism Dev Disord       Date:  2003-08

10.  A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan.

Authors:  Murray A Raskind; Kris Peterson; Tammy Williams; David J Hoff; Kimberly Hart; Hollie Holmes; Dallas Homas; Jeffrey Hill; Colin Daniels; Jess Calohan; Steven P Millard; Kirsten Rohde; James O'Connell; Denise Pritzl; Kevin Feiszli; Eric C Petrie; Christopher Gross; Cynthia L Mayer; Michael C Freed; Charles Engel; Elaine R Peskind
Journal:  Am J Psychiatry       Date:  2013-09       Impact factor: 18.112

View more
  3 in total

1.  Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.

Authors:  Neely Ivgy-May; Goeran Hajak; Gonnie van Osta; Sabine Braat; Qing Chang; Thomas Roth
Journal:  J Clin Sleep Med       Date:  2020-09-15       Impact factor: 4.062

Review 2.  Functional Changes of Orexinergic Reaction to Psychoactive Substances.

Authors:  Vincenzo Monda; Monica Salerno; Francesco Sessa; Renato Bernardini; Anna Valenzano; Gabriella Marsala; Christian Zammit; Roberto Avola; Marco Carotenuto; Giovanni Messina; Antonietta Messina
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

3.  Genetic and neuronal regulation of sleep by neuropeptide VF.

Authors:  Daniel A Lee; Andrey Andreev; Thai V Truong; Audrey Chen; Andrew J Hill; Grigorios Oikonomou; Uyen Pham; Young K Hong; Steven Tran; Laura Glass; Viveca Sapin; Jae Engle; Scott E Fraser; David A Prober
Journal:  Elife       Date:  2017-11-06       Impact factor: 8.140

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.